Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Bernard Moss · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $1,617,431 — During F7'24 progress has been made in developing improved vaccines for mpox and infections caused by other orthopoxviruses. We have continued our collaboration with the company Moderna using mRNAs expressing four modified mpox virus proteins encapsulated in a lipid particle. During the past year, t…
paolo lusso · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $1,410,429 — The development of an HIV vaccine has been hampered by unprecedented challenges, primarily due to the unique properties of the HIV-1 envelope (Env) trimer, which features an extraordinary assortment of immune-evasion tactics, including antigenic variation, heavy glycosylation of exposed surfaces and…
PETER SCHUCK · NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING · 2024 · $1,425,266 — In this project we seek to develop experimental methods for the study of macromolecular and particle size-distributions. This includes methods for the study of polymorphic dynamic multi-protein complexes that elude classical structural techniques, as well as methods for high-resolution particle size…
Lesia Dropulic · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $2,658,032 — Evaluation of the investigational vaccines in this project are part of the VRC mission related to biodefense and emerging pathogens. Targets include influenza, Ebola, Nipah, West Nile, malaria, and others. Published results from clinical trials have included: VRC 204: Ebola DNA vaccine study: Cli…
Daniel Cesar Douek · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $2,224,710 — The Genome Analysis Core (TGAC), within the Human Immunology Section, was set up in 2014 to fulfill many of the specialist sequencing needs of the Vaccine Research Center (VRC). Currently, the VRC is designing, producing and testing candidate immunogens aimed at eliciting broadly neutralizing antibo…
Kenneth C Bagley · ORLANCE, INC. · 2024 · $300,000 — PROJECT SUMMARY The currently marketed seasonal influenza vaccines have considerable impact on disease, but their efficacy relies on successfully matching the vaccine strains to future circulating virus strains. These vaccines induce neutralizing antibodies primarily against the head region of hemag…
Shakti Singh · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · 2024 · $134,800 — PROJECT SUMMARY: Candidate’s Career Development: Dr. Shakti Singh, an accomplished immunologist, presently holds the positions of Investigator and Assistant Professor at The Lundquist Institute (TLI) and the University of California, Los Angeles (UCLA), respectively. Over the past seven years at TLI…
Hao Yu · E&E BIOCLUB LLC · 2024 · $300,518 — PROJECT SUMMARY The success of mRNA-based vaccines and their modular technology have propelled RNA- based medicines from a relatively niche technology into the mainstream. As RNA-based medicines research intensifies, the manufacturing capacity of RNA is strained. This issue is exacerbated by the unp…
Michael R. Farzan · BOSTON CHILDREN'S HOSPITAL · 2024 · $891,681 — PROJECT SUMMARY What is the shortest path from the human antibody repertoire to sera that protects from an HIV-1 challenge? We propose here that this pathway starts from B-cell receptors (BCRs) with long, tyrosine-sulfated heavy- chain CDR3s (HCDR3s) encoded by D3-family of diversity (D) chain segme…
STEPHEN J MCSORLEY · UNIVERSITY OF CALIFORNIA AT DAVIS · 2024 · $225,839 — PROJECT SUMMARY A successful vaccine for systemic Salmonella infections will need to induce Th1 memory cells, but the tissue location and required functionality of these cells is poorly understood. Our preliminary data show that liver Tissue Resident Memory (TRM) CD4 T cells express higher levels of…
James L. Gulley · DIVISION OF BASIC SCIENCES - NCI · 2024 · $270,790 — Four CCR projects are currently supported by this Cancer Moonshot Bench to Beside and Back award: 1) TME informed NK cell therapy for pediatric sarcomas, led by Rosandra Kaplan (CCR) and Timothy Cripe (Nationwide Children's Hospital). The overall goal of this project is to develop natural killer (NK…
Leonidas Stamatatos · FRED HUTCHINSON CANCER CENTER · 2024 · $162,032 — ABSTRACT ADMINISTRATION CORE The Administrative Core will support the scientific and programmatic activities of our IPCAVD Program and provide the necessary infrastructure for the Program to achieve its overall research objectives and milestones in the most efficient and effective manner. This Core …
ELLIS L REINHERZ · DANA-FARBER CANCER INST · 2024 · $102,537 — SUMMARY – CORE A The Administrative Core A is requested to facilitate internal interactions among PIs of Projects 1-2, leaders of the four technology components, Core B (Antibody Neutralization), and the IAVI Biobank at both on- and off- campus sites as well as with the NIAID. Core A is responsible …
Steven James Madore · UNIVERSITY OF FLORIDA · 2024 · $43,615 — SHARED RESOURCE MANAGEMENT: ABSTRACT The University of Florida Health Cancer Center (UFHCC) members benefit from access to the UFHCC-managed Biostatistics and Quantitative Sciences Shared Resource (BQS-SR) and the institutionally-managed Flow Cytometry and Confocal Microscopy Shared Resource (CYT-SR…
Florian Krammer · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2024 · $191,272 — Summary SARS-CoV-2 vaccines have been developed in record time and are now widely used in many different countries around the globe. Project 1 will focus on characterizing immune signatures associated with SARS-CoV-2 immunization using different vaccine types. In Aim 1 we will leverage existing bios…
Joseph Paul Zackular · UNIVERSITY OF PENNSYLVANIA · 2024 · $380,746 — SUMMARY - PROJECT 2 (ANTIGEN DISCOVERY) Clostridium difficile is a spore-forming pathogen that causes a wide range of gastrointestinal (GI) disorders varying in severity from mild diarrhea to fulminant colitis and death. Difficulties in treating infections with conventional antibiotics and increasin…
E. John Wherry · MASSACHUSETTS GENERAL HOSPITAL · 2024 · $356,453 — Project Abstract Human immunology has changed radically in the past decade, accelerated, in part, by the COVID-19 pandemic. Despite this progress, we still lack knowledge of how to specifically induce optimal vaccine-induced T and B cell responses. One major gap in human immunology is the inability …
Kristina De Paris · WEILL MEDICAL COLL OF CORNELL UNIV · 2024 · $435,818 — ABSTRACT – Nonhuman Primate Core (NHP Core/ Core 1) The end of the HIV/AIDS epidemic will be achievable only when an effective vaccine regimen can achieve long-term protective immunity, similar to that of vaccines that have nearly eliminated other global pathogens. HIV acquisition risk begins in ute…
CHIUNG-YU HUNG · UNIVERSITY OF TEXAS SAN ANTONIO · 2024 · $430,315 — Project Summary An estimated 350,000 people in the United States become infected with Coccidioides annually. There is an unmet need to develop better chemotherapies and a vaccine for active immunization and/or immunotherapy against coccidioidomycosis (CM). We have previously created a recombinant ch…
Pamela J Bjorkman · CALIFORNIA INSTITUTE OF TECHNOLOGY · 2024 · $1,724,205 — PROJECT SUMMARY SHIV-infected rhesus macaques (RMs) develop HIV-1 broadly neutralizing antibodies (bNAbs) via Env-antibody (Ab) co-evolutionary pathways that recapitulate events in HIV-1 infected humans. This includes the frequency of bNAb induction, the viral epitopes targeted, and the immunogeneti…